Estrella Immunopharma's EB103 Achieves 100% Complete Response Rate in High-Risk B-Cell Lymphoma Patients
核心洞察
Estrella Immunopharma (搜索) completed the second dose cohort of its STARLIGHT-1 Phase I/II trial for EB103, achieving a 100% complete response rate at Month 1 in all evaluable patients with advanced B-cell non-Hodgkin's lymphomas.
The study enrolled high-risk patients unsuitable for commercial CD19 (搜索) products, including one with central nervous system lymphoma (搜索), with no treatment-related serious adverse events reported.
EB103 utilizes ARTEMIS® T-cell technology that differs from traditional CAR-T cells by using a cellular mechanism more closely resembling endogenous T-cell receptors to target CD19 (搜索)-positive cancer cells.
Estrella Immunopharma (搜索) has achieved a significant milestone in its STARLIGHT-1 Phase I/II clinical trial, with EB103 demonstrating a 100% complete response rate in the second dose cohort of patients with advanced B-cell non-Hodgkin's lymphomas. The clinical-stage biopharmaceutical company announced the successful completion of this cohort, marking a crucial step forward for its CD19 (搜索)-redirected ARTEMIS® T-cell therapy.
Promising Efficacy in High-Risk Patient Population
The second dose cohort achieved complete responses at Month 1 in all evaluable patients, representing a particularly challenging population of high-risk individuals who are not suitable candidates for commercial CD19 (搜索) products. Notably, the cohort included one patient with central nervous system lymphoma (搜索), a particularly difficult-to-treat condition that often carries a poor prognosis.
All patients enrolled in this cohort had relapsed/refractory B-cell NHL and had failed multiple prior lines of therapy, representing a population with significant unmet medical need. Despite the high-risk nature of these patients, no treatment-related serious adverse events were reported during this study phase.
"Completing the second dose cohort with a 100% CR rate marks a significant milestone in our EB103 clinical program," said Cheng Liu, PhD, Chief Executive Officer of Estrella. "We're especially encouraged by the favorable safety profile observed in this high-risk group, including a CNS-involved patient, which demonstrates the potential of EB103 as a safe and effective treatment for a broader population of cancer patients who have limited options."
ARTEMIS® Technology Platform
EB103 represents a novel approach to T-cell therapy, utilizing ARTEMIS® technology licensed from Eureka Therapeutics (搜索), Estrella's parent company. Unlike traditional CAR-T cells, the unique design of ARTEMIS® T-cells allows them to be activated and regulated upon engagement with cancer targets using a cellular mechanism that more closely resembles endogenous T-cell receptors.
Once infused, EB103 T-cells bind to and destroy CD19 (搜索)-positive cancer cells. CD19 is a protein expressed on the surface of almost all B-cell leukemias and lymphomas, making it an attractive therapeutic target for these malignancies.
Trial Design and Next Steps
The STARLIGHT-1 trial is an open-label, dose escalation, multi-center Phase I/II clinical trial designed to assess the safety of EB103 autologous T-cell therapy and determine the Recommended Phase II Dose in adult subjects aged 18 years and older with relapsed/refractory B-cell NHL. The study includes a dose escalation phase followed by an expansion phase.
Following completion of the second dose cohort, a Data and Safety Monitoring Board will review the cumulative study data to evaluate both safety and efficacy of EB103 and determine the Recommended Phase II Dose for the expansion phase. The DSMB is an independent group of experts that assesses the study's progress and makes recommendations to the trial's sponsor.
Broader Pipeline Development
Beyond EB103, Estrella is developing EB104, which also utilizes Eureka's ARTEMIS® technology to target both CD19 (搜索) and CD22 (搜索), another protein expressed on the surface of most B-cell malignancies. This dual-targeting approach represents the company's strategy to address potential resistance mechanisms and broaden therapeutic efficacy.
The company's mission focuses on harnessing the evolutionary power of the human immune system to transform the lives of patients fighting cancer and other diseases, with applications extending beyond oncology to autoimmune diseases (搜索).